Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84085
Title:
Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection.
Authors:
Qamruddin, A O; Oppenheim, B A; Guiver, M; Mutton, K J; Chopra, Rajesh
Abstract:
Potential risk factors for CMV infection and the use of quantitative CMV PCR screening to guide pre-emptive anti-CMV therapy were reviewed retrospectively in 32 allogeneic bone marrow transplant patients accrued over a 2-year period. Significant CMV PCR positivity (an indicator of CMV infection) developed in 34% of patients. When analysed by recipient CMV IgG serostatus, 69% of seropositive recipients developed significant CMV PCR positivity while none of the seronegative recipients did so (P = 0.00007). Considering only the seropositive recipients, 100% of those who received the low intensity campath-1H/fludarabine/melphalan 'mini-allograft' conditioning regimen developed significant CMV PCR positivity, while only 44% of those who had received cyclophosphamide/TBI did so (P = 0.0337). The mean time to first episode of significant CMV PCR positivity for those who had received campath/fludarabine/melphalan was 25 days while for those who had received cyclophosphamide/TBI, this was 66 days (P = 0.0372). For the first episode of significant CMV PCR positivity, the mean index and peak CMV PCR counts for those who had received campath/fludarabine/melphalan were 4.54 and 5.22 log copies/ml respectively, while for cyclophosphamide/TBI, the corresponding figures were 3.85 and 4.12 log copies/ml respectively (P = 0.2986 and P = 0.0472 for index and peak values). 85% of those who had significant CMV PCR positivity with the campath/fludarabine/melphalan regimen developed more than one such episode, while 50% of those receiving cyclophosphamide/TBI regimen did so (P = 0.491). Significant CMV PCR positivity was associated with symptoms in a proportion of patients (pyrexia 45%, cough 18%, rise in AST 72%). No patient developed overt CMV disease. CMV PCR is useful for guiding pre-emptive anti-CMV therapy and for monitoring response.
Affiliation:
Public Health Laboratory, Withington Hospital, Manchester, UK.
Citation:
Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. 2001, 27 (3):301-6 Bone Marrow Transplant.
Journal:
Bone Marrow Transplantation
Issue Date:
Feb-2001
URI:
http://hdl.handle.net/10541/84085
DOI:
10.1038/sj.bmt.1702778
PubMed ID:
11277178
Type:
Article
Language:
en
ISSN:
0268-3369
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorQamruddin, A Oen
dc.contributor.authorOppenheim, B Aen
dc.contributor.authorGuiver, Men
dc.contributor.authorMutton, K Jen
dc.contributor.authorChopra, Rajeshen
dc.date.accessioned2009-10-12T16:46:40Z-
dc.date.available2009-10-12T16:46:40Z-
dc.date.issued2001-02-
dc.identifier.citationScreening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. 2001, 27 (3):301-6 Bone Marrow Transplant.en
dc.identifier.issn0268-3369-
dc.identifier.pmid11277178-
dc.identifier.doi10.1038/sj.bmt.1702778-
dc.identifier.urihttp://hdl.handle.net/10541/84085-
dc.description.abstractPotential risk factors for CMV infection and the use of quantitative CMV PCR screening to guide pre-emptive anti-CMV therapy were reviewed retrospectively in 32 allogeneic bone marrow transplant patients accrued over a 2-year period. Significant CMV PCR positivity (an indicator of CMV infection) developed in 34% of patients. When analysed by recipient CMV IgG serostatus, 69% of seropositive recipients developed significant CMV PCR positivity while none of the seronegative recipients did so (P = 0.00007). Considering only the seropositive recipients, 100% of those who received the low intensity campath-1H/fludarabine/melphalan 'mini-allograft' conditioning regimen developed significant CMV PCR positivity, while only 44% of those who had received cyclophosphamide/TBI did so (P = 0.0337). The mean time to first episode of significant CMV PCR positivity for those who had received campath/fludarabine/melphalan was 25 days while for those who had received cyclophosphamide/TBI, this was 66 days (P = 0.0372). For the first episode of significant CMV PCR positivity, the mean index and peak CMV PCR counts for those who had received campath/fludarabine/melphalan were 4.54 and 5.22 log copies/ml respectively, while for cyclophosphamide/TBI, the corresponding figures were 3.85 and 4.12 log copies/ml respectively (P = 0.2986 and P = 0.0472 for index and peak values). 85% of those who had significant CMV PCR positivity with the campath/fludarabine/melphalan regimen developed more than one such episode, while 50% of those receiving cyclophosphamide/TBI regimen did so (P = 0.491). Significant CMV PCR positivity was associated with symptoms in a proportion of patients (pyrexia 45%, cough 18%, rise in AST 72%). No patient developed overt CMV disease. CMV PCR is useful for guiding pre-emptive anti-CMV therapy and for monitoring response.en
dc.language.isoenen
dc.subjectHaematologic Canceren
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAntigens, Viral-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshCytomegalovirus Infections-
dc.subject.meshFemale-
dc.subject.meshHematologic Neoplasms-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMass Screening-
dc.subject.meshMiddle Aged-
dc.subject.meshPolymerase Chain Reaction-
dc.subject.meshRetrospective Studies-
dc.subject.meshRisk Factors-
dc.subject.meshTransplantation Conditioning-
dc.subject.meshTransplantation, Homologous-
dc.titleScreening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection.en
dc.typeArticleen
dc.contributor.departmentPublic Health Laboratory, Withington Hospital, Manchester, UK.en
dc.identifier.journalBone Marrow Transplantationen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.